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Abstract 30 
The ankle degeneration ranging from focal osteochondral lesions to osteoarthritis (OA) can 31 
cause a total joint function loss. With rising life-expectancy and activity of the patients, 32 
various regenerative therapies were introduced aiming to preserve the joint function via the 33 
induction of cartilage and bone repair. Here, biological events and mechanical changes of the 34 
ankle degeneration were discussed. The regenerative therapies were reviewed versus the 35 
standard surgical treatment. We especially focused on the use of multipotential 36 
mesenchymal stromal cells (MSCs) highlighting their dual functions of regeneration and cell 37 
modulation with the focus on the emerging MSC-based clinical studies. Being at an early 38 
step, more basic and clinical research is needed to optimize the applications of all ankle 39 
regenerative therapies including MSC-based method. 40 
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1. Introduction  46 
A hallmark of the joint degenerative disease is the pathological involvement of different 47 
tissues mostly the damage of cartilage, as well as the thickening of the subchondral bones. 48 
These changes together cause pain and limitation or loss of the joint mechanical function [1]. 49 
$OWKRXJKIUHTXHQWO\UHIHUUHGWRDVWKHµDQNOHMRLQW¶WKHOLQNDJHEHWZHHQWKHORZHUOLPEDQG50 
foot consists of a complex of joint articulations. This complex comprises the talocrural (tibia-51 
talar), subtalar (talo-calcaneal) and transverse tarsal (talar-calcaneal-navicular) joints. The 52 
talocrural joint contributes the broadest range of motion during gait and provides stability 53 
during the load bearing [2]. For this review, our referral to the degeneration of ankle has 54 
alluded to the talocrural joint.  55 
Typically, the peak force experienced by the talocrural joint is of 4-7 times body 56 
weight, which is high compared to other joints of the lower limb and is carried over a much 57 
smaller contact area than the hip or knee [3]. However, the high level of joint congruency 58 
coupled with the differences in cartilage composition and structure between knee and ankle 59 
(i.e., higher proteoglycan with greater compressive rigidity in ankle) [4] explains why the 60 
ankle joint is less susceptible to primary osteoarthritis (OA). In contrast to knee and hip 61 
joints, the focal ankle osteochondral degeneration and secondary ankle OA are more 62 
common [5]. These degenerative ankle lesions are frequently caused by trauma, e.g., 63 
fracture or chronic ligament instability commonly because of the sport-related activities. 64 
Thus, most of these patients are young individuals [6]. Several factors can predispose to the 65 
development of post-traumatic ankle OA such as genetic factors, age, gender, muscle 66 
weakness, infection, and limb alignment [1, 7]. As mainly affect younger individuals 67 
with longer expected lifespan, the ankle OA as a painful joint disease could markedly 68 
influence the patient quality of life. The physical function scoring of 196 patients with 69 
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ankle OA has been reported as similar to or worse than that of patients with the end-70 
stage renal disease or congestive heart failure [8].  71 
No effective therapies are available to prevent the progression of ankle degeneration 72 
significantly, and the joint replacement might not be the best option for young patients 73 
with ankle OA [6]. Thus, the regenerative therapies aiming to preserve the tissues and 74 
function of the joint, have great potential for treating the young patients with ankle 75 
degeneration. Before considering the convenient type of the regenerative therapies for the 76 
ankle damage repair, it is essential to understand the two pathological events of degenerative 77 
ankle lesions; mechanical and biological and their interplay (Figure 1). The knowledge of 78 
these mechanisms will help to introduce or modify the therapeutic methods with best 79 
possible results.  80 
 81 
2. Ankle joint degeneration and the ankle OA; tissues involved 82 
Compared to knee OA, few animal models have been reproduced post-traumatic ankle 83 
OA only because age-related mouse models do not develop the ankle OA [9]. This 84 
trauma-like effect was performed via the resection of ankle-supporting ligaments creating 85 
three models according to excised ligament site, the medial-ligament model, the lateral-86 
ligament model, and the bilateral-ligament model. The cartilage degeneration of talotibial 87 
was mainly demonstrated in the medial-ligament model. These mouse models have helped in 88 
describing the similarities between the mouse and human ankles. For both human and 89 
mouse, the cartilage thickness in the ankle is about half that in the knee, and the density of 90 
ankle subchondral bone is higher than that in the knee [9]. Another rat ankle sprain model 91 
has been developed by resection of lateral ankle ligaments with potential use for 92 
investigating the subsequent effect of cartilage degeneration [10]. 93 
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While focal ankle degenerative lesions involve mainly the hyaline articular cartilage 94 
and the subchondral bone, other tissues can also be affected such as synovium, and muscles 95 
in the ankle OA [11]. These pathological tissue changes often trigger ankle pain on weight 96 
bearing, and negatively affect the normal daily activities. In an inflamed joint, synovial cells 97 
and chondrocytes are major sources of a large group of immune cytokines; interleukin-1, -15, 98 
-17 (IL-1), (IL-15), (IL-17) and tumor necrosis factor-alpha (TNF-Į). The increasing levels 99 
of these cytokines are associated with joint effusion and pain [12]. These inflammatory 100 
cytokines can interrupt the balance of the chondrocyte functions. Via the NFkB signaling, 101 
these cytokines stimulate the secretion of inducible Nitric Oxide Synthase (iNOS), 102 
Cyclooxygenase2 (COX2), and Prostaglandin E2 (PGE2) by chondrocytes. These changes 103 
are also associated with increased secretion of matrix proteolytic enzymes, 104 
metalloproteinases (MMPs). These together show that the inflammatory joint 105 
microenvironment is linked to the reduction in the synthesis and an increase in the 106 
degradation of the extracellular matrix collagen and ultimately the cartilage damage [13-15].  107 
Bone alterations constitute an integral part of the ankle OA pathogenesis. The 108 
radiologically-detected changes of subchondral bone usually include subchondral bone 109 
sclerosis and osteophyte formation with associated severe cartilage damage [16]. These bone 110 
changes are also detected in the knee and hip OA [17] suggesting that these pathological bone 111 
responses are universal to OA and not ankle specific. Interestingly, the changes denoting the 112 
abnormal remodeling of bone in the ankle are usually concomitant with increased numbers of 113 
the bone resorbing cells, osteoclasts and high expression of the pro-inflammatory IL-1, IL-6, 114 
and TNF-Į [18]. Additionally, the direct interactions between the bone forming cells, 115 
osteoblasts from subchondral tibia and femur, and chondrocytes lead to the reduction of 116 
proteoglycans and the induction of the MMP expression causing the cartilage damage in OA 117 
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[19]. Collectively, this confirms the direct relationship between the inflammation and the 118 
pathological bone changes as well as cartilage damage (Figure 1). 119 
 The weakness of the muscles within the joint can be correlated with the progressive 120 
cartilage damage as noted in knee OA [20]. Interestingly, the in vitro co-culture of muscle 121 
cells and chondrocytes enhances the resistance of the later cells to IL-1 and TNF-Į effects 122 
[21]. Furthermore, the weakness of muscles could reduce the cartilage supportive roles of 123 
muscle cells, which are known to activate the collagen production by chondrocytes [22]. 124 
Whether a similar effect of muscle weakness suggested for the cartilage damage 125 
progression in knee OA is not evident. However, an associated generalized atrophy of 126 
lower leg muscles detected in a radiological study of ankle OA suggested a consecutive 127 
rather than causative effect of muscle weakness [23]. 128 
 A connection between the obesity and the ankle pain is strong with the mechanical 129 
effect on skeletal alignment and muscle weakness could be critical contributing factors [24]. 130 
The intraarticular adipose tissues have a documented role in OA knee as shown in the 131 
experimental models or patients. The adipose tissues secrete high amount of the pro-132 
inflammatory mediators, IL-1, and adipokines [25]. A strong correlation was reported 133 
between one of the adipokines, the Leptin and the MMP expression levels in the synovial 134 
fluid from knee OA patients  [26] and between the mutation of Leptin and increase 135 
susceptibility to knee OA [27]. Similarly, another adipokine, Resistin also has a similar pro-136 
inflammatory role via induction of PGE2 and suppression of proteoglycans [28]. The effect 137 
of adipose tissue on cartilage showed for knee OA is less likely to be significant for the 138 
ankle OA. While in the knee joint, the infrapatellar fat pad lies in direct contact with 139 
the articular surfaces and cartilage [29], the ankle joint (talotibial) does not have such a 140 
fat pad. Thus, a similar pathological role for fat on cartilage in ankle OA is not 141 
expected. 142 
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 Altogether, different mechanisms in multiple tissues are participating in development 143 
and progression of ankle OA. The degenerative lesions involving mainly the cartilage and 144 
bone are usually manifested by pain and functional limitation of the joint.  145 
 146 
3. Ankle joint degeneration and the ankle OA; Mechanical events  147 
The stability of the ankle joint is determined both by the bony architecture and the soft tissue 148 
support [2]. The ankle sprains are one of the most common musculoskeletal injuries reported 149 
globally, accounting for more than 75% of all described ankle injuries [30]. Although several 150 
mechanisms could be involved in the ankle sprain, the most frequent is the lateral ankle 151 
sprain that involves inversion and excessive supination of the rearfoot during the landing/heel 152 
strike [31]. The severity of a sprain could range from a grade I classification, where the 153 
ligaments may be over-stretched, to a grade III sprain, where the ligaments are ruptured [32]. 154 
Arthroscopic studies of chronically instable ankles have identified the talar dome lesions 155 
associated with these conditions [33]. The osteochondral lesions of the ankle, associated with 156 
the sprain injury, are caused by a disruption between the cartilage and the underlying talar 157 
bone ranging from a small amount of local tissue bruising and up to an osteochondral fracture 158 
of the talus [34]. Due to the intrinsically small contact area of the ankle in a healthy joint, 159 
small changes to the biomechanics significantly alter the pressure of the talocrural joint and 160 
disrupt the local mechanics of the joint leading to adverse local contact conditions, such as 161 
increased shear stress within the cartilage resulting in its mechanical damage [33]. 162 
The ankle joint is also highly susceptible to the bone fracture, accounting for 9-14% 163 
of all fractures annually in the UK [35]. Altered biomechanics, disruption to the joint surface, 164 
and damage to the articulating cartilage may all lead to longer term degeneration of the ankle 165 
[36]. Imaging studies have identified arthritic changes in the ankle within five years 166 
following an inter-articular fracture. When progressed, patients with the ankle OA 167 
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demonstrate a significant change in the gait biomechanics compared with normal individuals. 168 
The off-loading compensatory mechanism employed by the patient may have some beneficial 169 
effect in reducing the shear stress within the cartilage. However, the biomechanical changes 170 
associated with the ankle OA also demonstrate a reduction in the ankle power and a 171 
substantial loss of muscle in the ankle region [37]. This may ultimately cause further 172 
mechanical changes locally within the joint as the function of the joint degenerates further 173 
and the bony deformity may arise in response to the mechanical changes.  174 
 175 
4. The classic treatment of degenerative ankle lesions 176 
Currently, the strategic choice of therapy for ankle degeneration depends on general factors 177 
such as age, health as well as the symptom severity, joint function, and the degree of skeletal 178 
tissue degeneration [1]. The first line of treatment for early and mid-stages of ankle OA is 179 
conservative to treat the pain and help to delay the need for the surgery. The conservative 180 
treatment is also the primary option for patients who do not qualify or with contraindications 181 
for joint sparing surgeries or ankle replacement. These conservative methods include dietary 182 
supplementation of glucosamines, visco-supplementation, Platelet-Rich Plasma (PRP), the 183 
ankle-foot orthoses (AFO), and physiotherapy. A daily oral dose of glucosamine sulfate has 184 
proven to be safe and significantly reduce the symptoms of lower limb OA, particularly 185 
knee [38]. However, more studies confirming the glucosamine effectiveness on ankle 186 
arthritis are needed. The visco-supplementation via the local injection of hyaluronic acid 187 
(HA) could facilitate the movement and help to release the pressure on the joints. 188 
Additionally, HA binds to CD44 molecule on the surface of synoviocytes and 189 
chondrocytes suppressing the expression levels of pro-inflammatory cytokines, MMPs 190 
and prostaglandins [39-41]. In a recent clinical study, the local injection of PRP into ankle 191 
has been reported as a safe procedure and helps to delay the need for surgical intervention 192 
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[42]. The AFO is used for the ankle to restore static and dynamic foot alignment, and to 193 
reduce the pain. However, the AFO should be used thoughtfully as it could cause 194 
movement restriction [43, 44]. 195 
When symptoms are persisting and with the progression of OA, one of the several 196 
surgical therapies can be chosen for the patient (Table 1). Osteotomy is a procedure used to 197 
correct an axial malalignment, a partial joint degeneration, or fracture mal-union [45]. The 198 
basis of osteotomy is resuming the alignment of the joint into normal contact areas of the 199 
articular surfaces and accordingly correcting the forces applied to the ankle joint. Several 200 
studies showed good results using the ankle osteotomy, but it has been reported that the 201 
symptoms and signs of synovitis can worsen over time [46]. Additionally, this procedure 202 
cannot be used at the end stage the ankle OA or in the old patients with low bone quality 203 
[47]. Although no biological boosting is included in this method, it becomes frequently 204 
applied in association with some regenerative approaches as described below. 205 
In the late stage of degenerative ankle lesions, arthrodesis is still considered as the 206 
gold standard surgical therapy. This procedure aims to fix the ankle bones by performing a 207 
fusion between the tibia and talus and this usually help to improve the weight-bearing 208 
activities of the ankle joint [48]. But arthrodesis could have low-cost effectiveness due to 209 
present risk of non-healing with the need for a second surgery and the high risk of developing 210 
OA [49]. In contrast to arthrodesis, ankle replacement is increasingly used mainly for the old 211 
and less active patients with severe joint damage [50]. However, ankle replacement could be 212 
associated with various post-operative complications such as instability, loosing, failure and 213 
periprosthetic fractures [51]. For both treatments (arthrodesis and ankle replacements), the 214 
criteria for the patient selection are a powerful tool that can make considerable differences in 215 
the complication and re-operation rate, but the activity restriction is still the main 216 
disadvantage for ankle fusion in particular. In summary, although variable choices are 217 
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available, the clinical outcomes of the surgical treatment are not always successful. 218 
Furthermore, the cadaveric studies have highlighted that clinical intervention does not fully 219 
restore the native ankle joint contact or the hind-foot mechanics [52] indicating that new 220 
improved therapies correcting the biology in addition to the mechanics of ankle are still 221 
required. 222 
 223 
5. Regenerative therapies of degenerative ankle lesions 224 
Different regenerative methods have been recently introduced aiming mainly to repair the 225 
cartilage tissues, delaying progressive bone changes, and avoid surgeries involving a 226 
restriction in the joint movement. These methods either include the grafting of bone/cartilage 227 
tissue or cultured chondrocytes or the stimulation of existing chondrocytes, i.e., 228 
osteochondral grafting, autologous chondrocyte implantation or arthrodiastasis respectively. 229 
Other methods work by concentrating and activating the resident bone/cartilage progenitor 230 
cells; mesenchymal (or multipotential) stromal cells (MSCs) using the microfracture 231 
technique or by external implantation of MSCs into the joint. These cell-based therapies 232 
usually aim to promote cartilage healing and probably limit the inflammatory response 233 
(Figure 1). 234 
 235 
i. Osteochondral grafting 236 
The osteochondral grafting or mosaicplasty involves the use of an osteochondral cylinder 237 
graft harvested from low-demand site, e.g., knee intercondylar region or lateral trochlea [53] 238 
or from the ipsilateral talar articular facet [54]. This method can be used for the lesions up to 239 
2 cm2 and it has been reported with promising results showing tissue regeneration and 240 
improvement of the joint symptoms [53, 54]. However, the limitation for the osteochondral 241 
grafting is usually the pain and bleeding at the donor site [55].  Additionally, little evidence 242 
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about the graft integration and survival has been shown with high rates of long-term clinical 243 
failure with need for a second surgery [56]. Together, alternative use of cells instead of 244 
tissues could be a better regenerative option as described below. 245 
 246 
ii. Autologous chondrocyte implantation  247 
Autologous chondrocyte implantation (ACI) involves the seeding of culture-expanded 248 
chondrocytes then locally implanting into the joint [57]. Although arthroscopic ACI has been 249 
used in the ankle with satisfactory effects [58], this technique still has several limitations 250 
including inadequate functions of chondrocytes particularly in the old individuals and the 251 
large-size cartilage defects. Additionally, the cost, the long-term preparation and the in vitro 252 
manipulation and the need for two surgical procedures are hard to overcome [59]. 253 
Interestingly, an osteochondral plug can be generated in vitro by combining the collagen-254 
based matrices seeded by human chondrocytes with devitalized sponge cylinders using a 255 
fibrin gel [60]. Additionally, an engineering of the chondrocytes could be a potential option 256 
targeting specific molecules such as miRNA-140 that has a regulatory effect on the 257 
expression of MMPs [61]. Such modifications in ACI can further improve the clinical results, 258 
but the donor age and the lesion size are essential factors still to be considered.  259 
 260 
iii. Arthrodiastasis 261 
Arthrodiastasis or the joint distraction is used in the young patients having normal alignment 262 
of the ankle joint [62, 63]. It includes using an external ring fixator together with performing 263 
a gradual distraction up to 5 mm. The rationale of this method is the activation of self-264 
regenerating abilities of the osteochondral tissue via differentiation of MSCs. When the joint 265 
is distracted, the resident synovial fluid-MSCs favorably adhere to the cartilage in distracted 266 
joints due to the reduction of synovial hyaluronic acid as shown in an experimental model of 267 
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knee OA [64]. Additionally, the alterations in intra-articular hydrostatic fluid pressure during 268 
arthrodiastasis are believed to stimulate the chondrocytes to produce proteoglycans and 269 
collagen helping the cartilage repair [65]. The clinical outcomes of the ankle arthrodiastasis 270 
have been reported as satisfactory with pain reduction, fibrocartilage formation, and 271 
decreased subchondral bone thickness indicating an improvement of the bone remodeling 272 
[65]. Nevertheless, this procedure could be associated with some complications such as 273 
infections, neurovascular injuries, damage to ankle ligaments and repair failure because of 274 
the patient non-compliance [66]. Together, arthrodiastasis has a regenerative value by 275 
different mechanisms activating intrinsic MSCs and chondrocytes, but more studies are still 276 
required to minimize complication risk.  277 
 278 
iv. Microfractures  279 
Microfracture repair of the articular cartilage lesions involves drilling holes in the 280 
subchondral bone together with the removal of the calcified cartilage parts [67]. As 281 
experimental research has shown that bone marrow-MSCs could help the cartilage repair, this 282 
technique aims to cause the bone marrow bleeding that then forming a clot that contains local 283 
MSCs to maintain the cartilage regeneration [68]. This microfracture technique has been used 284 
successfully particularly for young patients having small talar osteochondral lesions and mild 285 
osteosclerosis with substantial functional improvement [53, 69]. However, this procedure 286 
seems to be ineffective in talar osteochondral lesions larger than 1.5 cm2 [70]. Additionally, 287 
the history of trauma and the presence of osteophytes and unstable osteochondral defects are 288 
usually indicative of the poor outcomes [67, 70, 71].  The effect of the patient age on 289 
microfracture outcomes is controversial [68, 71]. The location of the degenerative lesion 290 
could affect on the microfracture outcomes, for example, the osteochondral lesions of 291 
lateral talus has been found to be correlated with positive functional results [72].  292 
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 In summary, although osteochondral grafting, ACI, arthrodiastasis and 293 
microfracture deliver satisfactory clinical outcomes over midterm follow-up stages, these 294 
methods frequently fail in the long term. To improve the outcomes of these regenerative 295 
methods, scaffolds can be implanted to support the tissue healing. Smart scaffolds made 296 
of multi-layered biomimetic structures have been reported to induce the formation of 297 
both bone and cartilage [73, 74]. In sheep model with osteochondral defects, bone and 298 
cartilage regenerative results were reported for those scaffolds that were used with or 299 
without autologous chondrocytes, suggests that the main mode of action of the scaffold 300 
is based on the recruitment of local cells [73]. A clinical study involved 30 patients with 301 
knee chondral or osteochondral lesions, has shown that smart nanostructured scaffolds 302 
fabricated of type I collagen and hydroxyapatite scaffold could promote cartilage and 303 
bone healing together [74].  For degenerative ankle lesions, studies are needed to test the 304 
efficacy of such smart scaffolds when combined with the microfracture technique for 305 
promoting the cartilage healing. 306 
 307 
v. Implantation of MSCs  308 
Source, function and rationale for the use of MSCs  309 
MSCs are widely existed within the musculoskeletal, the fat and synovial tissues and the 310 
synovial fluid. Although the in vivo markers are not fully defined and appear variable, MSCs 311 
are well-characterized in vitro after the culture-expansion by being plastic-adherent, 312 
expressing the surface markers, CD90, CD73, and CD105, but are not expressing 313 
hematopoietic lineage markers [75]. These cells have the multi-lineage differentiation 314 
capacity (including bone, cartilage, and fat) making them suitable for the ankle osteochondral 315 
tissue repair [75]. Additionally, MSCs could affect other cells particularly immune cells via 316 
the secretion of immunomodulatory mediators [76].  317 
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The therapeutic value of the MSC administration into joint has been primarily shown 318 
using preclinical OA knee models, where cartilage repair and increased type II collagen were 319 
documented [76]. In addition to cytokines and growth factors, MSCs can produce 320 
proteins that are important for the cartilage tissue formation and maturation such as 321 
collagens, fibronectin, glycosaminoglycan, and proteoglycans as shown using ex vivo 322 
cells [77]. In addition to the tissue regeneration, MSCs can respond to the local 323 
environmental signals such as cytokines and growth factors that are produced in response to 324 
tissue injury [76]. A good example for the paracrine effect of MSCs is their ability to 325 
suppress the proliferation and the effector functions of both innate and adaptive immune 326 
cells. This immunomodulatory effect could be of great benefit controlling the inflammatory 327 
response and preventing the inflammation-related tissue damage in the ankle OA [78]. 328 
Because of these beneficial properties, MSC implantation into the ankle joint has been 329 
employed in several studies, as discussed below.  330 
 331 
MSC-based clinical studies of the ankle OA   332 
Several clinical studies have reported the use of MSCs with success particularly when 333 
compared with one approach of the standard surgical treatment (Table 2). The ankle OA and 334 
focal osteochondral lesions, as well as ankle bone non-union have been targets for the MSC 335 
implantation in several studies during the last two decades. A large study assessing the 336 
adverse effects of using autologous bone marrow concentrates or culture-expanded MSCs in 337 
several cases of orthopedic patients including the ankle OA has demonstrated no risk of the 338 
application in human [79]. In another study, using a single injection of autologous bone 339 
marrow-derived culture-expanded MSCs in moderate to severe cases of the ankle OA has 340 
been shown to be safe with beneficial outcomes of the pain reduction, the functional 341 
improvement and the cartilage repair [80]. An ongoing clinical trial involving MSCs is a 342 
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investigating the side effects of intra-articular injection of cultured autologous bone marrow 343 
MSC in patients with ankle OA within six month-follow up (https://clinicaltrials.gov, 344 
NCT01436058). 345 
Instead of the use of culture-expanded MSCs, the bone marrow concentrate (BMC) 346 
could be a source of native MSCs, which have promising outcomes as a regenerative 347 
cell-based therapy helping the treatment of ankle OA or osteochondral lesions. This 348 
application of these native MSCs helps to avoid the complicated steps and high costs of 349 
ex vivo culture of MSCs [81]. Additionally, application of bone marrow concentrate 350 
could have another advantage as containing soluble factors helping cartilage and bone 351 
repair [82]. These factors include growth factors such as Transforming growth factor 352 
beta (TGF-ß), BMP-2, VEGF and Platelet-derived growth factor (PDGF) and 353 
inflammatory cytokines IL-1 and IL-8 [83]. 354 
Hernigou et al. showed that percutaneous injection of bone marrow MSCs within 355 
bone marrow concentrate for ankle non-unions could enhance the bone regeneration better 356 
than using iliac crest-harvested bone autograft [84]. Moreover, Hauser et al. reported in a 357 
case study, that the multiple local deliveries of whole bone marrow in conjunction with 358 
hyperosmotic dextrose for the treatment of the ankle OA, can reduce the pain and improves 359 
the joint function [85]. To provide a matrix for regeneration MSCs, Buda et al. used a 360 
concentrate of autologous bone marrow seeded on scaffold and enriched with platelet-rich 361 
fibrin (PRF) as a source of growth factors (such as TGF-ȕ) for osteochondral lesions of the 362 
talus. Their results proved that this combination of biological factors could improve the 363 
cartilage healing process as good as ACI and have an advantage of one step procedure instead 364 
of two [86]. Similar to PRF, platelet rich plasma (PRP) is a biological material containing a 365 
multitude of platelet-derived growth factors, chemokine, and immunomodulatory molecules 366 
with beneficial effects on MSC repair cells can be used clinically to enhance the MSC 367 
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proliferation and differentiation properties [87]. In other two studies, patients with focal talar 368 
osteochondral lesions were treated with bone marrow concentrate seeded onto collagen 369 
scaffold or hyaluronic acid membrane in comparison to ACI technique. The clinical and 370 
radiological outcomes of both therapeutic strategies were similar with hyaline cartilage 371 
formation over long-term follow-up [88, 89].  372 
In addition to bone marrow, adipose tissue was used as a source of MSCs. Injection of 373 
autologous adipose tissue-derived MSCs (after removal of other fat and connective tissue 374 
cells) into the ankle joint combined with microfracture has been shown to induce better 375 
cartilage repair when compared to the microfracture method only [90]. Another study is 376 
currently testing the safety and efficacy of autologous adipose-derived stromal vascular 377 
fraction that contains MSCs for the treatment of OA of different joints including hip, 378 
knee, thumb, and ankle joints (https://clinicaltrials.gov, NCT03166410).  379 
The synovial fluid could be another potential source of MSCs because MSCs derived 380 
from synovial fluid of ankle with osteochondral lesion showed similarity in phenotype 381 
compared to bone marrow-MSCs with a preserved capability of differentiation [91]. 382 
Regardless the MSC tissue source, using autologous rather than allogenic MSC-based 383 
therapies seem to predominate for therapy of the ankle OA, presumably due to the relatively 384 
young age of the patients with fewer concerns regarding their therapeutic efficacy that could 385 
deteriorate with aging.  386 
  387 
Challenges in MSC-based therapies 388 
Although autologous MSCs used in clinical trials had success with the advantage of less cost 389 
and manipulations, none of the above studies have investigated the immune modulatory role 390 
of MSCs that could influence the pro-inflammatory cytokines (IL-1, IL-15, IL-17, TNF-Į-391 
related cartilage damage. Also, the expression levels of these cytokines were not measured 392 
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after MSCs implantation. Hence, whether the positive clinical outcomes of the MSC use are 393 
related to the differentiation, secreted growth factors, regulation of immune response or 394 
combination, is still unclear. Although has QRFOLQLFDOHYLGHQFHWKH06&V¶WXPRULJHQLF395 
potential has been shown in experimental models because MSC-mediated 396 
immunosuppression and anti-apoptotic mechanisms could promote tumor progression [92]. 397 
This tumorigenic potential suggested that the immunomodulatory effects of MSCs should be 398 
carefully assessed mainly in patients with immune disorders and cancer. 399 
Although BM concentrates has many the advantages of, the doses of delivered 400 
MSCs in bone and cartilage degenerative lesions such as OA, remain poorly known and 401 
controlled. The low frequency of BM-MSCs among other BM cells together with wide 402 
variability related to the aspiration techniques and donor age and gender [93-95] could 403 
lead to variable outcomes of this therapy. Thus, it is important to determine the MSC 404 
quantity needed for satisfactory results similar to what has been shown for the healing 405 
of the fracture bone non-union [96]. We have reported recently how an assay using a 406 
flowcytometry to phenotype and quantify MSCs, could be a suitable tool to indicate the 407 
the effectivness of BM concentrates used for clinical regenerative applications [97]. 408 
Assessing the functionality and the survival of implanted MSCs is an important factor 409 
to be considered for therapy. Campbell et al. reported that in the tissues of hip OA patients, 410 
CD271+ endogenous MSCs within the subchondral bone tend to accumulate in the areas 411 
adjacent to cartilage defects [98]. These MSCs appear to be less proliferative and have lower 412 
mineralization capacities as well as a high expression of CXCR1 and CCR6 chemokine 413 
receptors indicating of their altered migration capabilities [98]. The functionality of 414 
autologous MSCs in the damaged areas of cartilage and bone in ankle OA remains to be 415 
further explored. Additionally, to compare their competency with donor-matched bone 416 
marrow and adipose MSCs. These data could explain the failure of tissue-resident MSCs to 417 
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repair the ongoing osteochondral damage in OA and as such, provide a strong rationale for 418 
the addition of extra µKHDOWK\¶MSCs to the defect sites or using allogeneic MSCs for these 419 
elder patients. The mechanisms of alterations of the MSC function at the sites of the damage 420 
remains uncertain, but have been linked to altered biomechanical signaling from mechanical-421 
sensor cells, osteocytes to MSCs leading to perturbations in their osteogenic differentiation 422 
and aberrant bone remodeling as shown in knee OA [99]. It is yet to investigate if similar 423 
processes are taking place in the ankle OA.  424 
Collectively, all these data indicate that the induction of cartilage tissue repair using 425 
MSCs should go together with the consideration of interactions with local biological 426 
microenvironment and mechanical factors. Despite encouraging results from the MSC-based 427 
clinical trials, many questions remain unresolved, particularly for the MSC survival and 428 
mechanisms of action upon implantation. Additionally, testing the effect of the mechanical 429 
correction when combined with the MSC implantation is essentially needed.  430 
 431 
6. Future perspective 432 
The complexity of the pathology of ankle OA with the focus on the cartilage repair could be a 433 
reason for the limited or the short-term effects of current regenerative therapies. Several 434 
changes such as muscle weakness or injuries and adipose tissue changes are influencing the 435 
cartilage and bone damage in OA. Thus, the repairing and restoring the functions of other 436 
joint tissue should be considered. Additionally, the combination of these regenerative 437 
therapies and the correction of mechanical loading following could have a significant 438 
advantage of the long-term regeneration of the damaged cartilage. The mechanical ankle 439 
correction should aim collectively to treat the bone abnormalities and to strengthen the 440 
muscles/ligaments. A direct link between inflammatory mediators and loss of chondrocyte 441 
functions has been shown. However, further molecular studies are needed to examine how 442 
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targeting inflammation could improve the cartilage repair therapies. Altogether, treating 443 
ankle degeneration should be planned for a whole joint and not only cartilage-specific.  444 
MSCs have the great potential to be a favorite reparative method for the ankle 445 
degeneration. But, again these cells should be used as a part of a combined therapy. 446 
Critically, the response of MSCs particularly in OA patients towards the mechanical 447 
stimulation is complicated and could affect the clinical outcomes. Therefore, further 448 
understanding of the signaling pathways initiated in response to the mechanical stimulation in 449 
MSCs is essentially required. This knowledge will help to optimize the use of MSCs for 450 
effective cartilage engineering. The use of matrices such as the collagen scaffold or the 451 
hyaluronic acid membrane is of great value to provide mechanical stability and consequently 452 
support the MSC differentiation and paracrine functions. Similarly, adding another 453 
therapeutic element via using the biological stimulators of MSC function such as PRP is 454 
highly recommended using biological factors. Similar to the diamond concept of bone repair 455 
[100], a combination of the progenitor cells (i.e., MSCs), scaffolds, growth factors, and 456 
corrected mechanics could be applied as a one combined modality for therapy of ankle focal 457 
osteochondral lesions or the ankle OA. However, implementing this concept would require 458 
further development of the suitable pre-clinical in vitro and animal models where the 459 
implantation of these factors could be reliably be tested individually and in combination. 460 
Uniquely, in addition to the mesenchyme differentiation capacity, MSCs can 461 
modulate surrounding cells and microenvironment by releasing various cytokines, growth 462 
factors, and chemokines. While tissue regenerative and paracrine functions of MSCs are 463 
strongly demonstrated in vitro, the phenotype, topography, and function of in vivo MSCs in 464 
the ankle OA is not clear and needs further investigations. Another consideration for the 465 
MSC-based therapy for the joint degeneration is the heterogeneity of MSCs with regards their 466 
abundance and the differentiation potential, particularly between donors. Thus, determination 467 
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of the optimal quantity given for therapy is necessarily required. Also, the search for new 468 
specific markers to select the best functioning MSCs is needed. If defective, an alternative 469 
solution could be the induction of a particular function of MSCs using the cell engineering 470 
technologies. This approach could aim to express the extracellular matrix proteins and the 471 
growth factors by MSCs or harnessing the cellular machinery that controls the MSC 472 
differentiation capabilities. Together, more experimental, and clinical studies are still 473 
required in parallel to deliver the best regenerative method for the joint degeneration in 474 
general and the ankle in particular. 475 
 476 
Executive summary  477 
x Ankle joint degeneration /OA 478 
 The pathological events of ankle local osteochondral lesions or OA usually 479 
involves both mechanical and biological elements, which could lead to 480 
progressive loss of joint function, especially in young patients. 481 
x Classic treatment of ankle degeneration/OA 482 
 Using surgical solutions such as joint replacement or arthrodesis for treating 483 
degenerative ankle lesions have high costs with long-term complications 484 
particularly with increasing patient life-expectancy and activity.  485 
x Regenerative therapy of ankle degeneration/OA 486 
 The challenges of current therapies demonstrate the essential need for 487 
regenerative treatments as alternative options preserving the joint tissue, 488 
controlling inflammatory joint environment, and maintaining natural mechanical 489 
functions.  490 
 The regenerative treatment should be planned to take in account correction of 491 
various mechanical and biological pathological elements.  492 
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x The clinical use of osteochondral tissues or mature chondrocytes 493 
 The various regenerative therapies involving the grafting of osteochondral tissues 494 
or implantation of mature chondrocytes (ACI) are still evolving, but have some 495 
limitations mostly related to tissue harvesting and/or costs. 496 
x Arthrodesis and Microfractures are other examples of regenerative therapies mainly 497 
dependent on activation of resident MSCs to promote the cartilage healing. 498 
x The rationale for clinical use of MSCs in therapy of ankle degeneration/OA 499 
 The clinical use of MSCs has a great potential for regenerative ankle therapy as 500 
MSCs can act as progenitors for cartilage and bone as well as being cell 501 
modulator influencing inflammatory microenvironment. 502 
 Although of limited popularity compared to the knee joint, MSC-based clinical 503 
studies in degenerative ankle lesions have promising results that are comparable to 504 
those of other regenerative methods.  505 
x Challenges and considerations for clinical use of MSCs  506 
 Biological factors should be considered for MSC-based therapy including the 507 
source and the donor-dependent function and numbers. Also, extent and co-508 
existence of specific biological signals such as TGF-Beta could affect the therapy 509 
outcomes. 510 
 The MSC chondrogenic differentiation can be particularly affected by the 511 
mechanical loading types and these factors can affect the therapeutic outcomes of 512 
MSCs.  513 
 To boost the results, the design of more effective clinical trials involving MSCs 514 
for treatment of the ankle degeneration could also include scaffolds and a 515 
biological modifier such as platelet growth factors. Finally, the mechanical forces 516 
constitute a vital element to be considered. 517 
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Figure 1: The mechanism of development of ankle OA and the proposed mechanism of 842 
action of cell-based therapy. 843 
Both biological and mechanical events are involved in the development of ankle OA. The 844 
mechanical injuries of the ankle such as sprain or fracture can shear stress and consequently 845 
cause bone changes as well as cartilage damage. Also, inflammatory cytokines released by 846 
inflammatory synovium and chondrocytes can, in turn, change the chondrocyte function and 847 
induce MMP production. Bone alteration is presumably can promote the secretion of MMPs 848 
when bone cells interact with chondrocytes. The cell-based therapy involving MSCs aims to 849 
prevent further cartilage damage/help repair and suppress the inflammation. 850 
